We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

36 hedge funds and large institutions have $1.54M invested in AYTU BioPharma in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

0.06% less ownership

Funds ownership: 0.71% → 0.64% (-0.06%)

7% less capital invested

Capital invested by funds: $1.65M → $1.54M (-$115K)

14% less funds holding

Funds holding: 42 → 36 (-6)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
36
Holders Change
-6
Holders Change %
-14.29%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$147K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$74.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$74K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$18.8K
5
Jane Street
Jane Street
New York
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$234K
2
Walleye Capital
Walleye Capital
New York
-$108K
3
AC
Ayrton Capital
Connecticut
-$84K
4
CH
CVI Holdings
Delaware
-$26K
5
WAM
Warberg Asset Management
Illinois
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$405K +$74K +19,663 +23%
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$284K – – –
Millennium Management
3
Millennium Management
New York
$225K +$147K +39,006 +190%
Vanguard Group
4
Vanguard Group
Pennsylvania
$184K +$139 +37 +0.1%
BlackRock
5
BlackRock
New York
$90.9K -$105 -28 -0.1%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$75K +$74.9K +19,897 New
Commonwealth Equity Services
7
Commonwealth Equity Services
Massachusetts
$58K +$18.8K +5,000 +48%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$46K -$139 -37 -0.3%
Prudential Financial
9
Prudential Financial
New Jersey
$33.9K +$6.4K +1,700 +23%
ACM
10
Allred Capital Management
Texas
$23.6K +$3.77K +1,000 +19%
State Street
11
State Street
Massachusetts
$18.5K – – –
Jane Street
12
Jane Street
New York
$17.4K +$14.7K +3,917 +579%
IA
13
IFP Advisors
Florida
$15K +$188 +50 +83%
Citigroup
14
Citigroup
New York
$9.9K +$9.86K +2,618 New
Northern Trust
15
Northern Trust
Illinois
$8.81K – – –
Group One Trading
16
Group One Trading
Illinois
$7.6K -$75 -20 -1%
TRCT
17
Tower Research Capital (TRC)
New York
$6K -$3.36K -892 -36%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$4.59K -$151 -40 -3%
Morgan Stanley
19
Morgan Stanley
New York
$3.87K +$4 +1 +0.1%
SPC
20
Sigma Planning Corp
Michigan
$3.21K – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$2.82K -$2.16K -574 -43%
ACA
22
Affinity Capital Advisors
California
$2.16K – – –
HAIM
23
Hunter Associates Investment Management
Pennsylvania
$2K – – –
HF
24
HRT Financial
New York
$2K +$2.94K +780 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.97K – – –
1
2

AYTU Hedge Fund Activity: Q4 2022 in Review

36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2022, worth a combined $1.54M — down 7% from $1.65M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of AYTU and 5 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, adding an estimated $147K. The largest seller was Sabby Management, exiting entirely with an estimated $234K sold.

  • 36 institutional investors held AYTU BioPharma (AYTU) as of Q4 2022, down from 42 in Q3 2022.
  • Funds reported $1.54M of AYTU BioPharma stock for Q4 2022, down 7% quarter-over-quarter.
  • 5 funds opened new AYTU BioPharma positions in Q4 2022 and 11 closed out, a net change of -6 holders.
  • The largest AYTU BioPharma buyer in Q4 2022 was Millennium Management, an estimated $147K added.
  • The largest AYTU BioPharma seller in Q4 2022 was Sabby Management, an estimated $234K sold.

Based on aggregated 13F filings for Q4 2022.